|
gptkbp:instanceOf
|
gptkb:person
|
|
gptkbp:almaMater
|
gptkb:University_of_Cambridge
St George's, University of London
|
|
gptkbp:awardReceived
|
gptkb:Fellow_of_the_Academy_of_Medical_Sciences
gptkb:Fellow_of_the_Royal_Society
gptkb:Knight_Bachelor
|
|
gptkbp:birthDate
|
1960-03-17
|
|
gptkbp:birthPlace
|
gptkb:Esher,_Surrey,_England
|
|
gptkbp:children
|
2
|
|
gptkbp:doctorateAdvisor
|
gptkb:Sir_John_Vane
|
|
gptkbp:education
|
gptkb:Trinity_College,_Cambridge
gptkb:St_George's_Hospital_Medical_School
|
|
gptkbp:employer
|
gptkb:UK_Government
GlaxoSmithKline
|
|
gptkbp:fieldOfWork
|
gptkb:medicine
gptkb:pharmacy
gptkb:science_policy
|
|
gptkbp:fullName
|
gptkb:Sir_Patrick_John_Thompson_Vallance
|
|
gptkbp:gender
|
male
|
|
gptkbp:honorificPrefix
|
Sir
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sir Patrick Vallance
|
|
gptkbp:knighted
|
2019
|
|
gptkbp:knownFor
|
science communication
public health advice during COVID-19
|
|
gptkbp:memberOf
|
gptkb:Academy_of_Medical_Sciences
gptkb:Royal_Society
|
|
gptkbp:nationality
|
British
|
|
gptkbp:notableEvent
|
gptkb:COVID-19_pandemic
|
|
gptkbp:notableRole
|
gptkb:Chief_Scientific_Adviser_to_the_UK_Government
|
|
gptkbp:notableWork
|
gptkb:UK_COVID-19_response
|
|
gptkbp:occupation
|
gptkb:physician
gptkb:scientist
clinical pharmacologist
government chief scientific adviser
|
|
gptkbp:positionHeld
|
gptkb:Government_Chief_Scientific_Adviser
President of Research and Development at GlaxoSmithKline
|
|
gptkbp:predecessor
|
gptkb:Sir_Mark_Walport
|
|
gptkbp:researchInterest
|
drug discovery
cardiovascular biology
|
|
gptkbp:residence
|
gptkb:London,_England
|
|
gptkbp:spouse
|
gptkb:Sophia_Vallance
|
|
gptkbp:successor
|
gptkb:Dame_Angela_McLean
|
|
gptkbp:termEnd
|
Government Chief Scientific Adviser, 2023
|
|
gptkbp:termStart
|
Government Chief Scientific Adviser, 2018
|
|
gptkbp:title
|
Sir
|
|
gptkbp:twitter
|
@uksciencechief
|
|
gptkbp:bfsParent
|
gptkb:Academy_of_Medical_Sciences
|
|
gptkbp:bfsLayer
|
5
|